Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.
Christopher T RitchlinPhillip J MeaseWolf-Henning BoehnckeJohn TesserElena SchiopuSoumya D ChakravartyAlexa P KollmeierXie L XuMay ShawiYusang JiangShihong ShengYanli WangStephen XuJoseph F MerolaIain B McInnesAtul DeodharPublished in: RMD open (2022)
NCT03162796, NCT03158285.